Navigation Links
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
Date:8/24/2011

d actionable information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and diagnostic, which may provide physicians with information highly relevant for the treatment of their patients with cancer.

About Clarient

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing advanced oncology testing and diagnostic services. Clarient's customers are connected to its Internet-based portal, PATHSITE® that delivers high-resolution images and critical interpretive reports based on its diagnostic testing. Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma.

www.Clarientinc.com

Biocept's CEE™ Platform

Biocept is developing the proprietary CEE™ (cell enrichment and extraction) platform, and a family of specialized CTC tests (OncoCEE™), which will be provided as a service to physicians and patients, as well as pharmaceutical and biotechnology companies through Biocept's CLIA-certified, CAP-accredited laboratory.  The CEE™ platform is comprised of micro-fluidic capture channels and
'/>"/>

SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
5. Biocept, Inc. Announces New CFO
6. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
10. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
11. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACE™ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014 BCC Research reveals in ... CELLS , the global market for stem cells is ... with a five-year compound annual growth rate (CAGR) of ... Americas with growth projections of $2.2 billion in 2014 ... http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications of ...
(Date:9/15/2014)... Cancer Immunotherapy Market : Immune ... is a new market research report announced by ... types of therapeutics that have become the major ... (which is often called "immuno-oncology") in recent years: ... immunotherapy. , The regular use of immunotherapy ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... Q4 2007 sales increased 78.8% compared to Q4 2006 -- ... Estimated sales for FY ... increased 89.4% compared to FY 2006, NEW YORK, March ... a leading provider in the,nutraceutical industry engaged in the development, ...
... WELLESLEY HILLS, Mass., March 5 Joseph F. Finn, ... ActivBiotics, confirmed,today that the sale of ActivBiotics, proprietary assets ... PM on March 14, 2008. There has been,substantial interest ... 48 bid packages being reviewed by companies, in addition,to ...
... NEW YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... Board of Directors,has elected Jean-Marc Huet senior vice ... In this role, Mr. Huet will be,responsible for ... as the global financial operations of the organization ...
Cached Biology Technology:China Yingxia International Announces Q4 and FY 2007 Estimates 2China Yingxia International Announces Q4 and FY 2007 Estimates 3Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Exxon Valdez spilled 11 million gallons of oil into ... another giant oil spill in the Gulf of Mexico ... Journal of Consumer Research , news coverage of ... of catalyzing changes in the way fossil fuels are ... coverage of these two events helped to resolve many ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a ... chosen as one of 18 "Showcase Companies" representing ... at the annual CED Tech Venture Conference on September ... Convention Center in Raleigh, North Carolina ... will lead a discussion during the "Digital Health Spotlight ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... 1, 2011 Tiny marine organisms called zooplankton can use ... areas of the ocean where oxygen levels are so low ... trouble as these areas expand due to climate change. ... said University of Rhode Island doctoral student Leanne Elder. "But ...
... 2011 (Bronx, NY) A longstanding medical mystery ... other cognitive problems despite potent antiretroviral therapy may have ... of Yeshiva University. Their findings are published in the June ... Even though antiretroviral treatment suppresses HIV replication and slows ...
... study co-authored by University of Florida researchers provides details on ... concern as warm summer waters attract more people to the ... July print edition of Pacific Science warns that ... may be considered prey. The sharks feed near ...
Cached Biology News:Climate change could turn oxygen-free seas from blessing to curse for zooplankton 2New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3
...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
... NPY Y2 Receptor antiserum This NPY ... spinal level and is currently being characerized in ... rat and mouse and appears to work better ... in rat. For full characterizarion in dorsal root ...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: